776 Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth.
http://science.sciencemag.org/content/356/6343/1188
775 Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
https://www.nature.com/nature/journal/v546/n7658/full/nature22794.html
774 argeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.
http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(17)30036-X
773 Inactivated vaccinia virus induces antitumor immunity that can overcome resistance to checkpoint inhibitors.
http://immunology.sciencemag.org/content/2/11/eaal1713
772 Anti-LAP antibody induces antitumor immunity by affecting both adaptive and innate immune mechanisms.
http://immunology.sciencemag.org/content/2/11/eaaj1738
771 The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
http://stm.sciencemag.org/content/9/391/eaal4682
770 Mouse and human tumour-associated macrophages express PD-1, which increases with cancer stage and induces decreased phagocytosis by macrophages; by contrast, PD-L1 removal increases phagocytosis in vivo, decreases tumour burden and increases survival of mice.
https://www.nature.com/nature/journal/v545/n7655/full/nature22396.html
769 Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
http://www.pnas.org/content/114/21/E4223
768 VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
http://www.nature.com/nm/journal/v23/n5/abs/nm.4308.html
767 Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
http://www.nature.com/nbt/journal/v35/n5/abs/nbt.3834.html
766 A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma.
https://www.nature.com/nature/journal/v545/n7654/full/nature22334.html
765 Whole-genome landscapes of major melanoma subtypes.
http://www.nature.com/nature/journal/v545/n7653/full/nature22071.html
764 Leukotriene B4 antagonism ameliorates experimental lymphedema.
http://stm.sciencemag.org/content/9/389/eaal3920
763 The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.
http://www.nature.com/ncb/journal/v19/n5/abs/ncb3513.html
762 Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.
https://www.nature.com/nature/journal/v545/n7652/full/nature22311.html
761 Modulating the therapeutic response of tumours to dietary serine and glycine starvation.
http://www.nature.com/nature/journal/v544/n7650/full/nature22056.html
760 The cross-talk between immune cells and blood vessel endothelial cells promotes pericyte coverage and decreases hypoxia in mouse tumour models, and correlative evidence suggests that these processes influence cancer prognosis in humans.
http://www.nature.com/nature/journal/v544/n7649/full/nature21724.html
759 Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
http://stm.sciencemag.org/content/9/385/eaak9670
758 Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.
http://science.sciencemag.org/content/356/6334/200
757 Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.
http://science.sciencemag.org/content/356/6334/200
|
